Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal.

Crinetics (CRNX) Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and ...

Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their Piper Sandler and Evercore representatives to schedule meetings.

A new discovery about brain receptors that control the breakdown of amyloid beta may open the door to new Alzheimer’s ...

Researchers at Karolinska Institutet in Sweden and the RIKEN Center for Brain Science in Japan have identified two receptors in the brain that control ...

The main market opportunities for CCR8-targeted immunotherapies lie in its potential to address unmet needs in cancer treatment by selectively depleting immunosuppressive Tregs in tumors, enhancing ...

For more than 70 years, hydralazine has helped doctors lower dangerously high blood pressure during medical emergencies, ...

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a ...